ERBB2 and cancer: Another approved ADC, trastuzumab deruxtecan (T-DXd), was developed by conjugating DXd to the previously approved HER-2 targeting monoclonal antibody (mAb) trastuzumab for the treatment of numerous HER2-expressing cancers.